Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Vaccinex Announces Early Stage SIGNAL-AD Trial Results For Pepinemab Antibody In Alzheimer's Disease; Findings Show Novel Mechanism Targeting Astrocyte Activation Delays Disease Progression

Author: Benzinga Newsdesk | July 31, 2024 09:01am

Results Echo Phase 2 Huntington's Disease Study; Presented By Principal Investigator Eric Siemers, MD, At Alzheimer's Association International Conference

Posted In: VCNX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist